Genetic alterations in primary melanoma in Taiwan.
Y-S Sheen, K-T Tan, K-P Tse...
https://pubmed.ncbi.nlm.nih.gov/31408190/Actively Recruiting
Led by National Health Research Institutes, Taiwan · Updated on 2025-05-06
250
Participants Needed
16
Research Sites
260 weeks
Total Duration
Cutaneous melanoma is the most aggressive form of skin cancer and is rare in Taiwan, with an incidence of about 1 in 100,000 people. This research focuses on acral lentiginous melanoma and mucosal melanoma, which are more common in Taiwan than in Caucasian populations and have distinct clinical and genetic features. These melanoma types in Asians often have higher recurrence rates after surgery, respond less to immunotherapy, and have shorter times without disease progression, leading to generally poor survival outcomes. The study observes patients with different stages of melanoma, including early-stage acral melanoma stage III, locally advanced acral melanoma stage III, resectable, advanced unresectable or metastatic melanoma stage IIIIV or recurrent, and those with advanced melanoma who have comprehensive genetic testing reports. Patients may provide tumor tissue samples for genetic analysis. The study tracks these groups to better understand the diseases progression and genetic alterations. Participants will be followed regularly for data collection, including tumor tissue analysis and medical history review. Researchers aim to evaluate how acral melanoma evolves over time in Taiwan. Patients are expected to have a life expectancy of more than three months and must be willing to provide tumor samples and comply with follow-up schedules. The study is observational and ongoing through December 2030.
CONDITIONS
The Registry Study of Genetic Alterations of Melanoma in Taiwan
C
Chien-Ya Hung, BS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Health Research Institutes, Taiwan
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 years
Participants are observed over time to evaluate the evolution of melanoma and collect relevant clinical data.
Regular follow-up visits depending on cohort assignment
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Y-S Sheen, K-T Tan, K-P Tse...
https://pubmed.ncbi.nlm.nih.gov/31408190/Chiao-En Wu, Chan-Keng Yang, Meng-Ting Peng...
https://pubmed.ncbi.nlm.nih.gov/32582554/John Wen-Cheng Chang, Jun Guo, Chia-Yen Hung...
https://pubmed.ncbi.nlm.nih.gov/28198155/Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs...
https://pubmed.ncbi.nlm.nih.gov/35020204/Felicity Newell, James S Wilmott, Peter A Johansson...
https://pubmed.ncbi.nlm.nih.gov/33067454/Felicity Newell, Yan Kong, James S Wilmott...
https://pubmed.ncbi.nlm.nih.gov/31320640/John Wen-Cheng Chang, Yen-Lin Huang, Yao-Yu Chang...
https://pubmed.ncbi.nlm.nih.gov/31814762/Nicholas K Hayward, James S Wilmott, Nicola Waddell...
https://pubmed.ncbi.nlm.nih.gov/28467829/National Health Research Institutes, Taiwan
Lead Sponsor